Upfront Cash ($M)

Upfront Equity ($M)

Contingent Equity ($M)

R&D Support ($M)

Dev / Reg Milestones ($M)

Other Milestones ($M)

Total Precommercial Payments ($M)

Sales Milestones ($M)

Upfront Share (%)

Marketing Fee (%)

Transfer Price (%)

Manufacture Cost + (%)

neurotrophic tyrosine kinase receptor 1 (NTRK1), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)

tiered royalties | upfront payment, R&D fees, and potential milestone payments totaling $189M

Royalties ranging from the low- to mid-teens | $660M in development, regulatory and commercial milestones

Co-Development, Co-Promotion, Option, Research

Central Nervous System, Liver & Gallbladder Diseases, Ophthalmic

Broad Focus Central Nervous System, Broad Focus Liver & Gallbladder Diseases, Broad Focus Ophthalmic

$50M upon signing and additional $25M on one-year anniversary of the contract execution date | Undisclosed development, regulatory, and sales milestones

Co-Development, Equity, License, Option, Research

$285M in milestones per therapeutic candidate, Genmab has option to up to three therapeutic candidates

Tiered royalties ranging from single-digit to high-teen percentages | $225M in pre-commercial milestones, including up to $15M in the first 18 months | Total potential future development, regulatory, and commercialization milestones up to $585M

Co-Development, Co-Promotion, License, Supply

Mid-single digit royalties | Up to $175M in development and commercial milestones, including sales milestones, per target

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, China, India, New Zealand, Other Asian, Southeast Asia

Tiered high single-digit to low double-digit royalties | Payments totaling up to $598M including $55M in upfront and near-term milestone payments

Broad Focus Autoimmune/Inflammatory, Broad Focus Cancer

mid-single digit to low double-digit royalties, per FibroGen's 6Q21 | $1.1B in option, clinical, regulatory, and commercial milestone payments across all three programs, per FibroGen's 6Q21

ROW double-digit royalties up to 20%, per iTeos' 6Q21 | 50% US PS, per iTeos' 6Q21 | $900M, based on $1.45 billion in agg milestones, per iTeos' 6Q21 | $550M in agg dev/reg milestones for 3 indications

Co-Development, Co-Promotion, License, Option

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, China, India, New Zealand, Other Asian, Southeast Asia

tumor necrosis factor receptor superfamily, member 4 (TNFRSF4) (CD134) (LY-70) (OX40) (TXGP1L) (TXGP1) (ACT35)

400 | Kyowa Kirin and Amgen will share global development costs, except in Japan, and U.S. commercialization costs | $850M in milestones

$600M for Licensed Only Products, per MacroGenics' 6Q21 | $30M in MacroGenics’ common stock at $31.30/sh, 50% premium to FMV, per MacroGenics' 6Q21 | mid single-digit to low teen royalties, per MacroGenics' 6Q21 | $800M in agg dev/reg milestones, per MacroGenics' 6Q21 | Zai has option to convert Lead Program to global 50% PS upon payment of $85M plus cost reimb, per MacroGenics' 6Q21

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, India, Japan, New Zealand, Other Asian

Tiered, double-digit royalties | $5M payment made during the first 12 months of the agreement or upon Nicoya achieving a certain predetermined development milestone | Up to $115M in development, regulatory and sales-based milestones

Eastern Europe, European Union, Other European, Russia, United Kingdom

Tiered royalties ranging from low double digits to mid-twenties | $35M in pre-revenue regulatory milestones

tiered royalties | AZ will provide research funding and Proteros is eligible for success-based research, development, and commercial milestone payments up to 62 million EUR (US$75M)

Double-digit royalty, up to $150 M | $5M in upfront payment and future milestone payments for first indication and up to $7.5M in milestones for subsequent indications

undisclosed upfront payment | Kite invested in Shoreline's April $43M series A financing | $2.3 billion in additional payments if certain development and commercial goals are met

Africa, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All South American Countries, Canada, Mexico

2,362,348 shares of common at $16.93/sh (45% premium over FMV), per Spero's 6Q21 | High single digit to low double-digit royalties, per Spero's 6Q21 | $80M in agg milestones, per Spero's 6Q21

Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis

Tiered double-digit royalties | $179M in clinical, regulatory, and commercial milestones

glutaminyl-peptide cyclotransferase (QPCT) (glutaminyl cyclase) (QC), beta-amyloid (AB)

double-digit royalties | Undisclosed upfront payment and development and sales milestones totaling $565M

low double-digit to mid-teen royalties, per Agenus' 6Q21 | $1.36B in agg milestones, per Agenus' 6Q21

$3M, per Calithera's 6Q21 | Low double-digit royalties, per Calithera's 6Q21 | $252M in agg milestones, per Calithera's 6Q21

Genetic Disorders, Other Central Nervous System

undisclosed royalties | $1.25 billion in development and commercial payments

Undisclosed tiered royalties | $125M in near to mid-term potential milestones | Clinical, regulatory and commercial payments for potential value of the deal beyond $1.2 billion

UPenn and Dr. Wilson hold equity interests in the G2 Bio Companies, and will be entitled to receive licensing revenues

IBD - Crohn's Disease, IBD - Ulcerative Colitis, Other Gastrointestinal

Tiered low double-digit royalties | Up to $200M in development and commercial milestones

$92M, per Milestone's 6Q21 | $5M of pre-funded warrants, per Milestone's 6Q21 | low to high double-digit royalty, per Milestone's 6Q21 | $15.5M, per Milestone's 6Q21

$245M in development and commercialization milestones/target | Tiered low-single to low-double digit royalties

$180M, per Mirati's 6Q21 | High-teen to low twenties royalties, per Mirati's 6Q21 | $93M, per Mirati's 6Q21

Broad Focus Ophthalmic, Broad Focus Respiratory

Tiered royalties | $1.4 billion in milestone payments across multiple programs

Iluvien, Medidur FA, fluocinolone acetonide intravitreal implant, DF-277, NSC-92339

high single-digit to mid-teen royalty if opt-out, per Crispr's 3Q31 | 40% PS to Crispr on CTX001, 50% on other Products, so long as no opt-out

€75M ($US90M) | sub-teen to mid-teen royalties on Combination Products, per CureVac's 2020 20-F | €75M in aggregate milestones ($US90M), per CureVac's 2020 20-F | CON profit split on all but Combination Products, per CureVac's 2020 20-F

$542M in agg milestones for sL65 to treat Fabry & Pompe diseases, plus $49M in agg milestones for LB-001, per LogicBio's 6Q21 | mid- to high- single digit royalty for sL65, per LogicBio's 6Q21

Liver & Gallbladder Diseases, Other/Miscellaneous

Genetic Disorders, Other Liver & Gallbladder Diseases

solute carrier family 10 sodium-dependent bile acid transporter member 2 (SLC10A2) (ASBT) (IBAT)

double-digit tiered royalties | $109M in regulatory and commercial milestones

$75M in upfront payments and research milestones paid during the research term, including equity investment | $1.3 billion in research, development, regulatory, and commercial milestones across up to five programs.

mechanistic target of rapamycin (serine/threonine kinase) (mTOR) (FRAP) (FRAP1) (FRAP2) (RAFT1) (RAPT1), phosphoinositide 3-kinase (PI3K)

Low to mid-teen royalties, per Celcuity's 6Q21 | $335M in agg milestones, per Celcuity's 6Q21

Broad Focus Central Nervous System, Genetic Disorders

$120M in upfront and preclinical research milestones | Undisclosed tiered royalties | $1.1 billion in clinical and commercial milestones for all three programs

$66M, per ATAI's IPO prospectus | double-digit royalties, per ATAI's IPO prospectus | $35M, per ATAI's IPO prospectus

Tiered royalties in the low- to mid-single digits | $121M in development and commercialization milestones and a promissory note that may be convertible into Biolojic equity at a future date

Undisclosed tiered royalties | BridgeBio is eligible to receive more than $2 billion in upfront, regulatory and commercial milestones

Co-Promotion, Development, License, Option, Research

$58M in sponsored R&D, per Cidara's 3Q21 | mid- to high- single digit royalty, per Cidara's 3Q21 | $695M in agg milestones, per Cidara's 3Q21

$444M in sales milestones | $31M in Series A Preferred Stock investment | Royalty rates ranging from high single digits to the low twenties | $43M in development fees

Tiered royalties ranging from low double-digits and up to 20% | $660M in development, regulatory and commercial milestones

Tiered low double-digit royalties | $105M in development and commercial milestones

Single-digit tiered royalties per 3/16/21 PR | $353M in agg milestones per 3/16/21 PR

$262.5M per target, per Adagene's IPO prospectus | mid-single digit royalty, per Adagene's IPO prospectus | $27.5M in dev & $100M in reg milestones per target, per Adagene's IPO prospectus

Autoimmune/Inflammatory, Central Nervous System

Boston Immune Technologies and Therapeutics

Australia, China, India, New Zealand, Other Asian, Southeast Asia

$16.6M inclusive of BeiGene's exercise of the option to license following initial proof-of-concept studies | $4 million in BITT’s Series A preferred stock financing | Up to $105M in development, regulatory, and sales milestones

Cell Therapy - Stem Cells/Factors, Oligonucleotides

$15M in Cytovia stock or an upfront cash payment of $15M if certain conditions are not met by 12/31/21 | single-digit royalty payments | $760M in development, regulatory, and sales milestones

$100 million in upfront and preclinical research payments | Equity investment of $10M in Ensoma’s Series A Preferred Stock | Up to low double-digit royalties | Up to $1.25 billion including development and commercialization milestone payments for all five programs

$725M in option, regulatory and commercial milestone payments | Mid single-digit to low double-digit tiered royalties

$290M for PD-1 & $170M for each Option Product | 25% of global dev costs, up to $25M/yr cap | 20% for PD-1 and 18% for each Option Product | $90M for PD-1 indications | $35M option exercise plus $85M for each Option Product | Junshi purchased $50M of Coherus shares at FMV of $20.06/sh at signing

$450M, per Mol Templates' 2020 10-K | mid-single digit to mid-teen royalties, per Mol Templates' 2020 10-K | $874.5M per Mol Templates' 2020 10-K | MTEM pays R&D costs thru designation of dev candidate for Initial Target

CD79b molecule immunoglobulin-associated beta (CD79B) (B29), Fc gamma receptor IIb (FCGR2B) (CD32B)

Up to $11.5 million in research, development and manufacturing funding | Low-to-mid double digit royalties | Up to $172M in development, regulatory and commercial milestones

Tiered royalties ranging from the high single digits to low teens | $132M in regulatory and commercial milestones

Co-Development, Co-Promotion, License, Option, Research

Autoimmune/Inflammatory, Central Nervous System

Broad Focus Autoimmune/Inflammatory, Broad Focus Central Nervous System

$100M for each auto/inflam product, and $150M for each CNS product, per Rigel's 3Q21 | mid-single digit to high-teens royalty for R552, and low double-digit for CNS, per Rigel's 3Q21 | $330M for auto/inflam products, per Rigel's 3Q21 | $255M for CNS products, per Rigel's 3Q21

low double digit royalty, per Scynexis' 3Q21 | $110M in agg milestones, per Scynexis' 3Q21

Co-Development, Equity, License, Option, Research

Coronavirus, Influenza, Respiratory Syncytial Virus/RSV, Other Infectious-Miscellaneous, Other Infectious-Viral

50/50 dev cost sharing for all programs, except Vir pays for VIR-2482 thru Ph II | $300M on option exercise, plus $200M reg milestones for VIR-2482

mechanistic target of rapamycin (serine/threonine kinase) (mTOR) (FRAP) (FRAP1) (FRAP2) (RAFT1) (RAPT1), T lymphocyte

Tiered royalties | upfront payment, regulatory and sales milestone payments totaling up to $271M

Tiered royalty ranging from mid-single digit to low double digit | $109M in development, regulatory and sales milestones

Broad Focus Autoimmune/Inflammatory, Other Autoimmune/Inflammatory

568.2K Zai shares @ $132/sh, per argenx' 2020 Form 20-F | $75M in dev cost reimb, per argenx' 2020 Form 20-F | Mid-teen to low twenties royalties, per argenx' 2020 Form 20-F | $25M on US approval, per argenx' 2020 Form 20-F

$350M per program, per Artiva's IPO prospectus | $14M per program, per Artiva's IPO prospectus | high single-digit to low teen royalties, per Artiva's IPO prospectus | $265M for second program | 588

Africa, Asia, Europe, Middle East, NAFTA, South America

All African Countries, All European Countries, All Middle East Countries, All NAFTA Countries, All South American Countries, Australia, India, New Zealand, Other Asian, Southeast Asia

Co-Development, Co-Promotion, License, Option

All NAFTA Countries, Eastern Europe, European Union, Japan, Russia, Scandinavia, United Kingdom

Co-Development, Distribution, Equity, License, Restatement

Africa, Asia, Europe, Middle East, NAFTA, South America

Comirnaty, Pfizer-BioNTech Covid-19 Vaccine, tozinameran, BNT162, PF-07302048, BNT162B2

$72M in 3/20 | $113M eq in 4/20 | $563M in agg milestones, per BioNTech's 2020 20-F

Undisclosed upfront payment | Investment from Lilly in exchange for a convertible note | Up to $60M per target in research, development and commercial milestones, total potential deal size valued at $300M.

Coalition for Epidemic Preparedness Innovations

$10.25M in cash payable $9M at closing and $1.25M by June 30, 2021 | $3M Convertible Junior Preferred Stock | $74M in development and commercial milestones | mid single-digit royalties

Royalties ranging from the mid-single to the mid-double digits | $192M in upfront and milestone payments per product

$24.5M for Xerava and $85M for Giapreza | double-digit royalties, per La Jolla's 2020 10-K

$250M in sales milestones per program, per Merus' 2020 10-K | 707K shares @ $28.295/sh, per Merus' 2020 10-K | mid-single to low-double digit royalty, per Merus' 2020 10-K | $290M for each program, per Merus' 2020 10-K

€220 M (US$267M) in upfront, development and commercial milestonesfor first target

$215M, per Turning Point's 2020 10-K | mid-teen to low twenties royalties, per Turning Point's 2020 10-K | $121M, per Turning Point's 2020 10-K

tiered royalties | $458M in development and commercialization milestones

Yangtze River Pharmaceutical, Shanghai Haini Pharmaceutical

$40M upfront from JV, per Allogene's 2020 10-K | Overland purchase 51% of JV for $117M, per Allogene's 2020 10-K | low to mid-single digit royalties, per Allogene's 2020 10-K | $40M in reg milestones from JV, per Allogene's 2020 10-K | 49% of JV owned by Allogene, per Allogene's 2020 10-K

up to low double digit royalties, per Atara's 2020 10-K | $610M in agg milestones, per Atara's 2020 10-K

mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1)

JPY0.8 billion (US$7M) | High-single digits to low double-digit tiered royalties | JPY2.5 billion (US$23M) upon Phase I initiation | JPY49.6 billion (US$452M) in additional development and commercial milestones